Clinical Report: Association of Fecal Microbiome Profiles with HIV Stages
Overview
Revise to emphasize the role of ART duration and CD4+ T cell counts in microbiome changes.
Background
HIV infection leads to significant alterations in gut microbiota, contributing to immune dysfunction and systemic inflammation. Understanding the fecal microbiome's role in HIV progression is crucial, especially in regions like sub-Saharan Africa, where the burden of HIV is highest. This study addresses the gap in knowledge regarding the gut microbiome of PLHIV in Uganda, a region with unique dietary and geographical influences.
Data Highlights
Parameter
Findings
Participants
202 adults living with HIV
Microbiome Analysis
16S sequencing of fecal samples
Key Associations
Microbiome composition linked to ART duration and CD4+ T cells
Key Findings
Lower alpha diversity observed in PLHIV compared to HIV-uninfected individuals.
Specific taxa such as Bacterioides uniformis and Prevotella copri are overrepresented in PLHIV.
Persistent dysbiosis noted even after 12 months of ART initiation.
Microbial translocation correlated with immune activation and lower CD4+ T cell counts.
Geographical and dietary factors significantly influence gut microbiome composition.
Clinical Implications
Clinicians should consider the altered gut microbiome in PLHIV when managing their care, particularly regarding ART adherence and monitoring immune recovery. Understanding these microbiome changes can inform dietary and therapeutic interventions to improve patient outcomes.
Conclusion
The study underscores the importance of the fecal microbiome in understanding HIV progression and highlights the need for tailored interventions in PLHIV, particularly in resource-limited settings like Uganda.
